AUTOLUS THERAPEUTICS PLC (AUTL) Stock News

NASDAQ:AUTL - Nasdaq - US05280R1005 - ADR - Currency: USD

2.31 -0.06 (-2.53%)

After market: 2.25 -0.06 (-2.6%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AUTL Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Yahoo Finance - Mentions: ELTX

Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings

14 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

14 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

17 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

2 months ago - By: Benzinga

What 4 Analyst Ratings Have To Say About Autolus Therapeutics

3 months ago - By: Benzinga - Mentions: MSC ELUT ACIW JYNT ...

Earnings Scheduled For May 8, 2025

17 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

23 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

2 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

2 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Participate in Upcoming Investor Conferences

3 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

3 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

3 months ago - By: Yahoo Finance - Mentions: DHI CMG

Autolus Therapeutics plc (AUTL): Analysts See 697% Upside Potential

3 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

3 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

3 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

3 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

3 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

5 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

5 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

5 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

5 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

5 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Participate in Upcoming Investor Conferences